logo-loader
viewCircassia Pharmaceuticals PLC

Director/PDMR Shareholding

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;} .ab{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ab{}p.ce{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cf{color: black; font-family: "Arial","sans-serif"; font-size: 14.0pt; font-weight: bold}p.cg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.ca{font-family:"Arial","sans-serif";color:black}p.ch{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.ci{color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold}span.cj{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}span.bv{font-size:10.0pt;font-family:"Arial","sans-serif"} p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}span.bu{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}table.cl{width:429.85pt;margin-left:-10.8pt;border-collapse:collapse}tr.bm{height:4.0pt}td.bp{width:291.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: justify; text-decoration: underline}span.bs{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}td.bn{width:116.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal} tr.bj{height:6.35pt}td.bl{width:291.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.35pt}td.bk{width:116.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.35pt}tr.be{height:11.65pt}td.bg{width:291.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.65pt}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-decoration: underline}p.cq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}td.bf{width:116.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.65pt}table.cr{width:461.15pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.bb{width:17.3pt;border:solid #A6A6A6 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.cs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 1.45pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none}span.bx{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}td.ay{width:422.85pt;border:solid #A6A6A6 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.ct{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none}span.ba{font-size: 10.0pt;font-family:"Arial","sans-serif";color:black}td.aw{width:17.3pt;border:solid #A6A6A6 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.cu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 36.9pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none; text-indent: -36.9pt}td.au{width:98.1pt;border-top:none;border-left: none;border-bottom:solid #A6A6A6 1.0pt;border-right:solid #A6A6A6 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;layout-grid-mode:char;text-autospace:none}td.at{width:313.35pt;border-top:none;border-left: none;border-bottom:solid #A6A6A6 1.0pt;border-right:solid #A6A6A6 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; layout-grid-mode: char; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-autospace: none}td.ar{width:422.85pt;border-top:none; border-left:none;border-bottom:solid #A6A6A6 1.0pt;border-right:solid #A6A6A6 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";layout-grid-mode: char; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-autospace: none}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 1.45pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none}table.cz{border-collapse:collapse;border:none}td.an{width:75.7pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; line-height:normal;layout-grid-mode:char;text-autospace:none}td.am{width:67.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.al{width:75.7pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ak{width:67.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-indent:-18.0pt;line-height:normal;layout-grid-mode:char;text-autospace: none}span.ah{font-size:10.0pt;font-family:Symbol;color:black}p.dd{margin-top:3.0pt;margin-right:5.65pt;margin-bottom:3.0pt;margin-left:5.65pt;line-height:13.0pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:5.65pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:normal}span.de{font-family:"Arial","sans-serif";color:black;font-size:10.0pt}span.ac{font-family:"Arial","sans-serif"} /**/
RNS Number : 3495O
Circassia Pharmaceuticals Plc
01 October 2019
 

Director/PDMR Shareholding

 

Oxford, UK - 1 October 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that on 30 September 2019, Jonathan Emms, Chief Operating Officer of Circassia, purchased 300,000 Ordinary Shares on the London Stock Exchange at a price of 16.5 pence per share.

 

Contacts

Circassia

Steve Harris, Chief Executive Officer

Julien Cotta, Chief Financial Officer

Rob Budge, Corporate Communications

 

Tel: +44 (0)1865 405560

 

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Dr Christopher Golden

 

Tel: +44 (0) 20 7418 8900

 

finnCap (Joint Broker)

Geoff Nash / Alice Lane

 

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Freddie Barnfield

 

Tel: +44 (0) 20 7260 1000

 

FTI Consulting

Simon Conway / Ciara Martin

Tel: +44 (0) 20 3727 1000

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.         

Details of the person discharging managerial responsibilities / person closely associated

a.         

Name

Jonathan Emms

2.         

Reason for the notification

a.         

Position/status

Chief Operating Officer

b.         

Initial notification

/Amendment

 

Initial notification

3.         

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.         

Name

Circassia Pharmaceuticals plc

b.         

LEI

2138006YAT138TOGA556

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Shares of 0.08p each

 

 

GB00BJVD3B28

b.         

Nature of the transaction

Purchase of Ordinary Shares

 

c.         

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

16.5147p

300,000

      

d.         

Aggregated information

·      Aggregated volume

·      Price

 

 

 

n/a

 

e.         

Date of the transaction

2019-09-30

f.         

Place of the transaction

London Stock Exchange, AIM

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBGBDGGDGBGCB

Quick facts: Circassia Pharmaceuticals PLC

Price: 16.9

Market: LSE
Market Cap: £63.78 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19